Docket # 02N-0115

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | Erik Henrikson | FDA - CDER | |
| 2 | Tom MENIGHAN | APhA | |
| 3 | Susan Winckler | APhA | |
| 4 | Sharon Olmstead | Pharmacia | |
| 5 | Hon-Sum Ko | FDA - CDER | |
| 6 | Margo Heron | BMS | |
| 7 | Matthew Boyl | BMS | |
| 8 | [illegible] | Duke | |
| 9 | Rupert Ambrose | MasiMax Resources, Inc | |
| 10 | David Horowitz | FDA / CDER | |
| 11 | SYBIL RICHARDS | NACDS | |
| 12 | GARY WIRTH | NACDS | |
| 13 | | | |
| 14 | | | |
| 15 | | | |
| 16 | | | |
| 17 | | | |
| 18 | | | |
| 19 | | | |
| 20 | | | |

02N-0115

LST4

Docket # 02N-0115

# Attendance Record
## Part 15 Hearing
## Risk Managment of Prescription Drugs
## May 22, 2002

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | Galson, Steven | FDA | |
| 2 | Fitzpatrick, Cynthia | FDA | fitzpatrickc@cder.fda |
| 3 | Ray, Seth | FDA-OCC | |
| 4 | Plaza-Adonis Laure | Berguer, Bockorny, Inc | lpa@bbhb.com |
| 5 | Rachel Sonneller | Hogan and Hartson | |
| 6 | Gary Stein | ASHP | gstein@ashp.org |
| 7 | Tom Hassall | MERCK | 301 941-1410 |
| 8 | Houn, Florence | FDA | |
| 9 | Slifman, Nancy | FDA | slifman@cber.fda.gov |
| 10 | Hollon, Tom | CLINICAL RESEARCHER | thollon@starpower.net |
| 11 | Bob Gagne | Collet McVoy Public Affairs | gagnee@colletmcvoy.com |
| 12 | Bull, Jonca | FDA | BULLJ@cder.fda.gov |
| 13 | RW Soller, PhD | CHPA | wsoller@chpa-info.org |
| 14 | J. Waugh | Roche | Joanna.waugh@roche.com |
| 15 | | | |
| 16 | | | |
| 17 | | | |
| 18 | | | |
| 19 | | | |
| 20 | | | |

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

Docket # 02N-0115

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | Sameer Bagai | SAS | Sameer.Bagai@SAS.com |
| 2 | Evelyn M Rodriguez | Novartis | evelyn.rodriguez@pharma.novartis.com |
| 3 | CAROL KRUEGER | CDER/OC | KRUEGERC@cder.fda.gov |
| 4 | KATHRYN BESS | Roche Pharmaceuticals | Kathryn.Bess@roche.com |
| 5 | AL BESS | NOVARTIS | AL.BESS@PHARMA.NOVARTIS.COM |
| 6 | Alla R. Bobbitt | FDA Reports | a.rutstein@elsevier.com |
| 7 | Dee Kennedy | FDA | Kennedyd@cder.fda.gov |
| 8 | Kala L Paul | Corvallis Grp LLC | kalapaul@aol.com |
| 9 | Matthew A. Wikler | ViroPharma, Inc. | mwikler@viropharma.com |
| 10 | Ann Mackey | FDA | |
| 11 | NORMAN MARKS | FDA | |
| 12 | MARY KREMZNER | FDA | |
| 13 | PAUL STOLLEY | Public Citizen | |
| 14 | Nancy Myers | Lehmann | |
| 15 | Tora Frilda | USP | |
| 16 | Steve Anderson | FDA | |
| 17 | Jerry Phillips | FDA | |
| 18 | Helen Winkle | FDA | |
| 19 | Stephen Matthews | DVC, LLC | smathews@dynport.com |
| 20 | Toni Piazza-Hepp | FDA | |

Docket # 02N-0115

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | Joan Antokol | Novartis | Joan.antokol@pharma.novartis.com |
| 2 | Ellen Cooper | Viropharma | ecooper@viropharma.com |
| 3 | Judi Vills | Deggegroup | jsills@deggegroup.com |
| 4 | Jill Weelesen | Pharm Cape | jillwz@ac.com |
| 5 | John Balian | Pfizer | john.d.balian@groton.pfizer.com |
| 6 | Suanna Bruinooge | Amer. Soc. of Clinical Oncology | bruinoos@asco.org |
| 7 | MARY GOSS | FDA | GOSSM@EDER.FDA.GOV |
| 8 | ALLAN M KORN | BCBSA | allan.korn@bcbsa.com |
| 9 | Christine Simmon | BCBSA | christine.simmon@bcbsa.com |
| 10 | GLORIA TAYLOR | GAO | taylorge@gao.gov |
| 11 | [illegible] | Novartis | 301-468-5602 |
| 12 | Linda Carter | Pharmacia | 301-998-6115 |
| 13 | CHUEN TEG | Johnson + Johnson | 609-730-3415 |
| 14 | Gary Smith | Univ of Maryland | 410-872-1116 |
| 15 | Min Chen | FDA | 301-827-3169 |
| 16 | RITA RUBIN | USA TODAY | 703-854-3494 |
| 17 | Pat Kuntz | FDA | 301-827-4414 |
| 18 | Shiew Mei Huang | FDA | 301-827-7688 |
| 19 | Debra Bowen | HJ | |
| 20 | Diane Zuck | CPR | |

Docket # 03N-0115

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | MARK SENAK | MANNING SELVAGE LEE | MARK.SENAK@MSLPR.COM |
| 2 | Martin Himmel | FDA | Himmelm@cosr.FDA.Gov |
| 3 | Veena Menon | FDA WEEK | veena.menon@inpnews.com |
| 4 | Benjamin P. Lewis | Brand Institute, Inc. | blewis@brandinst.com |
| 5 | Brenda Kilkany | FDA | KilkanyB@CDER.FDA.GOV |
| 6 | Constance Bulawka | FDA | Email - Ctr. Director |
| 7 | Jenna Fourrel | Durham Herald-Sun | ~~jenn~~ jfourrel@northwestern.edu |
| 8 | Angela Jeanssonne | ADA | ajeansonne@ada-net.org |
| 9 | Lee Moe | WCEY | lee.moe@wc.ey.com |
| 10 | Sandra Eskin | AARP | eskin@erols.com |
| 11 | Debra Shiozawa | AstraZeneca | debi.shiozawa@astrazeneca.com |
| 12 | Kathleen Uhl | FDA | uhlk@cder.fda.gov |
| 13 | Richard Lewis | FDA | LewisR@CBER.FDA.GOV |
| 14 | MERLENE LOCKRAGE | AstraZeneca | merlene.Lockrage@astrazeneca.com |
| 15 | Claudia Karwoski | FDA | Karwoskic@cder.fda.gov |
| 16 | Lorna Totman | CHPA | LTotman@chpa-info.org |
| 17 | Melissa Kaplan | SWHR | melissa@womens-health.org |
| 18 | Mark Hirsch | FDA | hirschm@cder.fda.gov |
| 19 | ASHOK BATRA | FDA | batra@cder.fda.gov |
| 20 | Cassie Chew | BNA News | cchew@bna.com |

Docket # 02N-0115

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | Richard Civil | Cephalon, Inc | e.mail RCivil@cephalon.com |
| 2 | Berger, Mitchell | TPG | Mitchell_berger@thanson.com |
| 3 | Shawn Clever | Berlex | Shawn_clever@berlex.com |
| 4 | CHRISTOPHER BLANGO | ASTRA Zeneca | chris.blango@astrazeneca.com |
| 5 | Joel Schiffenbauer | FDA | schiffenbaue@cder.fda.gov |
| 6 | Ginette Jacob | Merlex | Montville, NJ. |
| 7 | Vicki McLaughlin | Miller Reporting | |
| 8 | Debbie Travers | Endo Pharmaceuticals | travers.debbie@Endo.com |
| 9 | Mary Alice Raudenbush | Endo Pharmaceuticals | Raudenbush.Mary@Endo.com |
| 10 | Gretchen S. Dieck | Pfizer | gretchen.dieck@pfizer.com |
| 11 | Jim KOTSANOS | LILLY | Kotsanos@Lilly.com |
| 12 | Joseph Cranston | AMA | joseph_cranston@ama-assn.org |
| 13 | PAUL SELIGMAN | FDA | seligmanp@cder.fda.gov |
| 14 | MANFRED OSTER | Aventis | manfred.oster@aventis.com |
| 15 | Wanju Dai | Aventis | wanju.dai@aventis.com |
| 16 | Mary Ellen TURNER | Wyeth | turnerm3@wyeth.com |
| 17 | Amy Renner | DataPhase IV Inc. | arenner@dataphaseiv.com. |
| 18 | SYD GILMAN | ELAN | SYDNEY.GILMAN@ELAN.COM |
| 19 | JUSTINA MOLZON | FDA | molzonj@cder.fda.gov |
| 20 | ELIZABETH LEVIN | BIOGEN, INC. | liz_levin@biogen.com |

Docket # 02N - 0115

# Attendance Record
## Part 15 Hearing
## Risk Managment of Prescription Drugs
## May 22, 2002

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | JEFF BLOOM | THE TITLE II COMMUNITY AIDS NATIONAL NETWORK | (202) 265-0058 JLB2130@aol.com |
| 2 | Nancy Smith | CDER | |
| 3 | Melodi McNeil | FDA/CDER/OPASS | MCNEILM@CDER.FDA.GOV |
| 4 | Joel C. Harder | American Red Cross, B/H Q | harderj@usa.redcross.org |
| 5 | John Jenkins | FDA/CDER/OND | jenkinsj@cder.fda.gov |
| 6 | Joe Oliver | FDA/CDER/OTCOM | OLIVERN@CDER.FDA.GOV |
| 7 | Paul Lagarenne | Aventis Pharma | paul.lagarenne@aventis.com |
| 8 | Youngsook Choi | Aventis | youngsook.choi@aventis.com |
| 9 | Charles Clark | Dataphase IV | cclark@dataphaseiv.com |
| 10 | Carol Rossmann | Wyeth | ROSSMAC@wyeth.com |
| 11 | Haley Kaplowitz | Genentech | haley@gene.com |
| 12 | Paul Sheehan | SI International | Paul.sheehan@SI-intl.com |
| 13 | Sandra Kweder | FDA | kweder@cder.fda.gov |
| 14 | Kathleen Bongiovanni | FDA | bongiovanni@cder.fda.gov |
| 15 | Sam YONREN | MILLENNIUM | YONREN@MPI.COM |
| 16 | Yasuko Hanahisa | Eli Lilly & Co | hanahisa_yasuko@lilly.com |
| 17 | Nancy Ostrove | Eli Lilly | ostrovenm@lilly.com |
| 18 | Sidney Wolfe | Public Citizen Health Research Grp | SWOLFE@CITIZEN.ORG |
| 19 | J. Carnistra | American Pharmac. Assoc. | jcarnistra@aphanet.org |
| 20 | Laura Governale | FDA/CDER/DDMAC | governalel@cder.fda.gov |

Docket # 02N - 0115

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | Michelle Ertischek | Pinney Associates | MERTISCHEK@PINNEYASSOCIATES.com |
| 2 | Alan Goldhammer | PhRMA | agoldham@phrma.org |
| 3 | Shawn Hodges | Lilly | hodges_shawn@lilly.com |
| 4 | Anita Ducca | American Red Cross | DuccaA@USA.RedCross.org |
| 5 | Jane Murp | Novartis Pharm | Gen Yachnik at Novartis |
| 6 | PETER FARROW | PFIZER | peter_farrow@sandwich.pfizer.com |
| 7 | Jennifer Goldstein | Patton Boggs | jgoldstein@pattonboggs.com |
| 8 | JUDY TIAN | Solvay Pharmaceuticals | judy.tian@solvay.com |
| 9 | Tom Clark | Amer. Soc. Consultant Pharmacists | tclark@ascp.com |
| 10 | E. ABRAO | BERLEX | eduardo_abrao@berlex.com |
| 11 | Liz Bloss | Bracco | LBloss@diag.bracco.com |
| 12 | Robert Koelle | AstraZeneca / Widener Law | Robert.Koelle@astrazeneca.com |
| 13 | Mike Warner | GYMR | MWarner@GYMR.com |
| 14 | PATRICK CAUBEL | Johnson & Johnson | PCaubel@PRDUS.jnj.com |
| 15 | ROSEMARY COOK | Johnson & Johnson | |
| 16 | Susan Bishop | APhA | sbishop@aphanet.org |
| 17 | Yolanda Fleming | National Medical Assn. | YFleming@NMAnet.org |
| 18 | DAVID SLAVIN | PFIZER | david_slavin@groton.pfizer.com |
| 19 | Stephen Goldman | SAG Consulting Services LLC | saggcs@aol.com |
| 20 | M. Mehta | Thomson Med Econ | mukesh.mehta@melec.com |

**Attendance Record**
**Part 15 Hearing**
**Risk Managment of Prescription Drugs**
**May 22, 2002**

Docket # 02N-0115

| | NAME | ORGANIZATION | CONTACT INFORMATION |
|---|---|---|---|
| 1 | BRADLEY GALER, MD | ENDO PHARMACEUTICALS, INC | galer.bradley@endo.com |
| 2 | JAMES CONOVER | ENDO Pharm Inc | James.Conover@endo.com |
| 3 | Betsy Raymond | Pfizer Inc. | betsy-m-raymond@groton.pfizer.com |
| 4 | Jeff Chasnow | Pfizer | jeffrey.b.chasnow@pfizer.com |
| 5 | PGW Maybury | HCPC | PGMayberry@AOL.COM |
| 6 | LES PAUL MD | MERCK-MEDCO | LES_PAUL@MERCKMEDCO.COM |
| 7 | LOURDES MIFRAU | AVENTIS | LOURDES.IFRAU@AVENTIS.COM |
| 8 | PETER BOTTINI | MYLAN | PBBOTTINI@MYLANLABS.com |
| 9 | Jeanine Best | FDA | bestj@cder.fda.gov |
| 10 | H. SWARZ | IPC, Inc | SWARZ@INTERPharmUSA.com |
| 11 | Thomas Abrams | FDA | abramst@cder.fda.gov |
| 12 | ANNE TRONTELL | FDA | trontella@cder.fda.gov |
| 13 | Bob Temple | FDA | Temple@cder.FDA.gov |
| 14 | Ron Chesemore | Pfizer | Ronald-g-chesemore@groton.pfizer.com |
| 15 | Mark Baumgartner | GlaxoSmithKline | mab86932@GSK.com |
| 16 | Marissa Seligman | Vivophama | marissa.seligman@vivopharma.com |
| 17 | JAE HONG LEE | Nat. Ctr. for Pol. Res. for Wom. + Fam. | JL@centerforpolicy.org |
| 18 | JOHN KELLY | PhRMA | JKELLY@PHRMA.ORG |
| 19 | Tom Cupmann | Eli Lilly | TCupmann@Lilly.com |
| 20 | JOHN FERGUSON | BIOGEN | JOHN-Ferguson@Biogen.com |